FDA Grants Expanded Approval To Emergent BioSolutions’ Smallpox Vaccine For Use In People At High Risk Of Mpox Infection

Reuters (8/30, Santhosh) reported the FDA “granted expanded approval to Emergent BioSolutions’ smallpox vaccine for use in people at high risk of mpox infection.” The FDA clearance “makes the vaccine the second approved shot against mpox in the U.S.” Emergent’s vaccine, called ACAM2000, “cannot be administered to those with weakened immune systems, including people with HIV.” Rather than “an injection, the Emergent shot is given through a series of small pokes on the skin using a two-pronged needle.”